StockData
QuidelOrtho Corp logo

QuidelOrtho Corp (QDEL) stock

QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 7, 2026Score 6/3084% below fair value
$13.25−0.51 (-3.71%)

Close on Oct 30, 2026Market cap $908.62MP/E –Yield –

Earnings

QuidelOrtho's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$631.00M
+2.8% on a year earlier
adjusted diluted earnings per share (“EPS”), Q2 FY2026
$0.13
$0.12 a year earlier
Latest guidance
Issued
Aug 6, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of QuidelOrtho's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 28, 2026Nov 4, 2026Expected–––––
Q2 FY2026ended Jun 28, 2026Aug 6, 2026after the close$631.00M+2.8%-$1.36$0.13Release
Q1 FY2026ended Mar 29, 2026May 5, 2026after the close$620.00M-10.5%-$1.35-$0.04Release
Q4 FY2025ended Dec 28, 2025Feb 11, 2026after the close$724.00M+2.3%-$1.92$0.46Release
Q3 FY2025ended Sep 28, 2025Nov 5, 2025after the close$700.00M-3.7%-$10.78$0.80Release
Q2 FY2025ended Jun 29, 2025Aug 5, 2025after the close$614.00M-3.6%-$3.77$0.12Release
Q1 FY2025ended Mar 30, 2025May 7, 2025after the close$693.00M-2.5%-$0.19$0.74Release
Q4 FY2024ended Dec 29, 2024Feb 12, 2025after the close$708.00M-4.7%-$2.28$0.63Release
Q3 FY2024ended Sep 29, 2024Nov 7, 2024after the close$727.00M-2.3%-$0.30$0.85Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024after the close$637.00M-4.2%-$2.20-$0.07Release
Q1 FY2024ended Mar 31, 2024May 8, 2024after the close$711.00M-16.0%-$25.50$0.44Release
Q4 FY2023ended Dec 31, 2023Feb 13, 2024after the close$743.00M-14.3%$0.10$1.17Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

QuidelOrtho's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenues (reported)FY2026$2.52B – $2.60B–NewAug 6, 2026
Total revenues (reported)GAAPFY2026$2.70B – $2.75B–NewMay 5, 2026
Adjusted EBITDAnon-GAAPFY2026$540.00M – $560.00M–NewAug 6, 2026
Adjusted EBITDAnon-GAAPFY2026$615.00M – $630.00M–NewMay 5, 2026
Adjusted diluted earnings per sharenon-GAAPFY2026$1.80 – $2.00–NewMay 5, 2026
Adjusted diluted EPSnon-GAAPFY2026$0.65 – $0.90–NewAug 6, 2026
Free cash flownon-GAAPFY2026$100.00M – $120.00M–NewMay 5, 2026
Adjusted EBITDA marginnon-GAAPFY202621% – 22%–NewAug 6, 2026
Adjusted EBITDA marginnon-GAAPFY202623%–NewMay 5, 2026

Guidance vs results

The last range QuidelOrtho gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Adjusted diluted EPS$2.00 – $2.15$2.12Σ4QWithin range
FY2025Revenue$2.68B – $2.74B$2.73BΣ4QWithin range

Guidance history

Every forecast QuidelOrtho put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 6, 2026Adjusted EBITDAFY2026$540.00M – $560.00MNew
Aug 6, 2026Adjusted diluted EPSFY2026$0.65 – $0.90New
Aug 6, 2026Adjusted EBITDA marginFY202621% – 22%New
Aug 6, 2026Total revenues (reported)FY2026$2.52B – $2.60BNew
May 5, 2026Adjusted EBITDAFY2026$615.00M – $630.00MNew
May 5, 2026Adjusted diluted earnings per shareFY2026$1.80 – $2.00New
May 5, 2026Free cash flowFY2026$100.00M – $120.00MNew
May 5, 2026Adjusted EBITDA marginFY202623%New
May 5, 2026Total revenues (reported)FY2026$2.70B – $2.75BNew
Nov 5, 2025Adjusted EBITDAFY2025$585.00M – $605.00MNew
Nov 5, 2025Adjusted diluted EPSFY2025$2.00 – $2.15New
Nov 5, 2025Adjusted EBITDA marginFY202522%New
Nov 5, 2025Total revenues (reported)FY2025$2.68B – $2.74BNew
Aug 5, 2025Adjusted EBITDAFY2025$575.00M – $615.00MReaffirmed
Aug 5, 2025Adjusted diluted EPSFY2025$2.07 – $2.57Reaffirmed
Aug 5, 2025Adjusted EBITDA marginFY202522%Reaffirmed
Aug 5, 2025Total revenues (reported)FY2025$2.60B – $2.81BReaffirmed
May 7, 2025Adjusted EBITDAFY2025$575.00M – $615.00MReaffirmed
May 7, 2025Adjusted diluted EPSFY2025$2.07 – $2.57Reaffirmed
May 7, 2025Adjusted EBITDA marginFY202522%Reaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases QuidelOrtho filed with the SEC as exhibits to Form 8-K or 6-K

  1. QuidelOrtho Reports Second Quarter 2026 Financial Results
    Results
  2. QuidelOrtho Appoints Micah Young as Chief Financial Officer
    Update
  3. QuidelOrtho Reports First Quarter 2026 Financial Results
    Results
  4. QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
    Results
  5. Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer
    Update
  6. QuidelOrtho Reports Fourth Quarter and Full-Year 2025
    Results
  7. QuidelOrtho Third Quarter 2025 Financial Results
    Update
  8. QuidelOrtho Reports Third Quarter 2025 Financial Results
    Results
  9. SAN DIEGO, CA August 21, 2025 — QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or
    News
  10. QuidelOrtho Reports Second Quarter 2025 Financial Results
    Results
  11. QuidelOrtho Reports First Quarter 2025 Financial Results
    Results
  12. QuidelOrtho Reports Fourth Quarter and Full-Year 2024
    Results
  13. QuidelOrtho Announces Preliminary Unaudited Revenue for
    Results
  14. QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group
    News
  15. QuidelOrtho Reports Third Quarter 2024 Financial Results
    Results